경구 항바이러스제 시장 : 시장 규모 - 적응증별, 약제 클래스별, 유통 채널별, 지역별 예측(2022-2032년)

Global Oral Antiviral Market is valued approximately USD 36.7 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.10% over the forecast period 2024-2032. Oral antiviral drugs, taken by mouth, are pivotal in combating viral infections. They function by impeding viral replication, entry into host cells, or release from infected cells. These drugs serve as frontline treatments for various viral infections including influenza, herpes simplex virus, hepatitis B and C, HIV, among others. Additionally, they play a crucial role in both preventing and treating infections, tailored to specific circumstances. Some are utilized preventively, particularly for individuals at high risk of contracting viruses such as HIV. Furthermore, rising investing in research and development to expand the range of oral antiviral drugs available. This included developing new drugs targeting a broader spectrum of viruses are gaining attention towards Global Oral Antiviral Market.

The Global Oral Antiviral Market is driven by rising prevalence of viral infections, such as hepatitis, influenza, and HIV, is generating increased demand for effective oral antiviral drugs. This demand is further fueled by the growing availability of improved healthcare infrastructure, particularly in emerging markets. In addition, rising advancements and innovations within the pharmaceutical sector geared towards manufacturing oral antiviral drugs present a promising opportunity for the oral antiviral market. The uptick in approvals for a range of oral antiviral agents, alongside an expanding array of clinical trials conducted by key players worldwide, is poised to positively influence market growth. However, absence of favorable reimbursement policies and side effects of the oral antiviral drugs is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the Global Oral Antiviral market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue. The upsurge in viral infections such as HIV and hepatitis C, coupled with the presence of key players offering oral antiviral solutions and the bolstering of healthcare infrastructure, are driving the of growth in the oral antiviral market in North America. Moreover, the Asia-Pacific region is poised for fastest expansion due to heightened investments in oral antiviral agent development, a rise in cases of viral infections, and an increasing number of pipeline medications tailored for treating such infections. These factors collectively propel the growth trajectory of the oral antiviral market throughout the forecast period 2024-2032.

Major market player included in this report are:

• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Gilead Sciences, Inc.
• Viatris Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc

The detailed segments and sub-segment of the market are explained below:

By Indication

• Hepatitis
• Human Immunodeficiency Virus (HIV)
• Influenza
• Others

By Drug Class

• Protease inhibitors
• Reverse transcriptase inhibitors
• Others

By Distribution Channel

• Hospital pharmacies
• Drug store and retail pharmacies
• Online providers

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Oral Antiviral Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Oral Antiviral Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Indication
  • 2.3.2. By Drug Class
  • 2.3.3. By Distribution Channel
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Oral Antiviral Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Oral Antiviral Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Oral Antiviral Market Size & Forecasts by Indication 2022-2032

• 5.1. Hepatitis
• 5.2. Human Immunodeficiency Virus (HIV)
• 5.3. Influenza
• 5.4. Others

Chapter 6. Global Oral Antiviral Market Size & Forecasts by Drug Class 2022-2032

• 6.1. Protease inhibitors
• 6.2. Reverse transcriptase inhibitors
• 6.3. Others

Chapter 7. Global Oral Antiviral Market Size & Forecasts by Distribution Channel 2022-2032

• 7.1. Hospital pharmacies
• 7.2. Drug store and retail pharmacies
• 7.3. Online providers

Chapter 8. Global Oral Antiviral Market Size & Forecasts by Region 2022-2032

• 8.1. North America Oral Antiviral Market
  • 8.1.1. U.S. Oral Antiviral Market
    • 8.1.1.1. Indication breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Drug Class breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Oral Antiviral Market
• 8.2. Europe Oral Antiviral Market
  • 8.2.1. U.K. Oral Antiviral Market
  • 8.2.2. Germany Oral Antiviral Market
  • 8.2.3. France Oral Antiviral Market
  • 8.2.4. Spain Oral Antiviral Market
  • 8.2.5. Italy Oral Antiviral Market
  • 8.2.6. Rest of Europe Oral Antiviral Market
• 8.3. Asia-Pacific Oral Antiviral Market
  • 8.3.1. China Oral Antiviral Market
  • 8.3.2. India Oral Antiviral Market
  • 8.3.3. Japan Oral Antiviral Market
  • 8.3.4. Australia Oral Antiviral Market
  • 8.3.5. South Korea Oral Antiviral Market
  • 8.3.6. Rest of Asia Pacific Oral Antiviral Market
• 8.4. Latin America Oral Antiviral Market
  • 8.4.1. Brazil Oral Antiviral Market
  • 8.4.2. Mexico Oral Antiviral Market
  • 8.4.3. Rest of Latin America Oral Antiviral Market
• 8.5. Middle East & Africa Oral Antiviral Market
  • 8.5.1. Saudi Arabia Oral Antiviral Market
  • 8.5.2. South Africa Oral Antiviral Market
  • 8.5.3. Rest of Middle East & Africa Oral Antiviral Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Bristol-Myers Squibb Company
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Johnson & Johnson Services Inc.
  • 9.3.3. AbbVie Inc.
  • 9.3.4. Amneal Pharmaceuticals LLC
  • 9.3.5. Gilead Sciences, Inc.
  • 9.3.6. Viatris Inc.
  • 9.3.7. Merck & Co., Inc.
  • 9.3.8. Teva Pharmaceutical Industries Ltd.
  • 9.3.9. F. Hoffmann-La Roche Ltd
  • 9.3.10. GlaxoSmithKline plc

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes